- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04967716
Genetics of Charcot-Marie-Tooth Dystrophy and Related Diseases
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
[Background] Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of the most common hereditary peripheral neuropathy, with a prevalence of about 1/2500-4000. The inheritance mode can be autosomal dominant inheritance, autosomal recessive inheritance, X-linked dominant inheritance and X-linked recessive inheritance. The typical clinical manifestations are progressive, length-dependent weakness and atrophy of the distal limbs, accompanied by hypoesthesia and weakened tendon reflexes. But the generalized peroneal muscular atrophy also includes hereditary motor neuropathy and hereditary sensory neuropathy, which represents the evolution of a disease spectrum from motor nerve to motor sensory nerve and sensory nerve, collectively referred to as CMT and its related diseases. CMT can be divided into demyelinating type (CMT1), axonal type (CMT2) and intermediate type. There are more than 80 kinds of genes discovered so far, and genetic diagnosis plays a vital role in the treatment of peroneal muscular atrophy and genetic counseling.
[Purpose]
- To clarify the gene lineage distribution of CMT genes in CMT patients in my country, draw a frequency map of CMT gene distribution, and assist in determining the genetic diagnosis strategy of CMT diseases;
- Discover new mutations and newly published types of known genes, and perform gene-phenotype correlation analysis
- Perform whole-exome sequencing on some families that have not been clearly diagnosed to find new pathogenic genes or related genes of CMT, so as to enrich the genetic and clinical types of CMT.
[Design] This is a cross-sectional study. All patients will be collected for clinical and electrophysiological data. Patients and families who meet the enrollment criteria will be tested for blood tests. The inspection strategies are as follows: (1) Use MLPA method for PMP22 gene Duplicate or deletion mutation check (charge); (2)) Use high-throughput sequencing method to detect the currently known gene panel (gene panel) (charge); (3) Check the process (1) and (2) Some patients and families whose disease-causing genes have not been detected by the inspection methods are tested by whole-exome sequencing (scientific research, free of charge).
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Xiaoxuan Liu
- Telefonnummer: 13910982101
- E-Mail: zhangys0317@126.com
Studieren Sie die Kontaktsicherung
- Name: Xiaoxuan Liu
- E-Mail: zhangys0317@126.com
Studienorte
-
-
-
Beijing, China
- Rekrutierung
- Peking University Third Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Meet the clinical diagnostic criteria of peroneal muscular atrophy; Sign informed consent
Exclusion Criteria:
- Those who have recently received blood transfusion treatment will not be able to collect blood samples.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Peroneal muscular atrophy
Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity.
It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886.
The prevalence is about 1/2500-4000.
It is the most common hereditary peripheral neuropathy.
Inheritance includes all forms of Mendelian inheritance.
The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
|
Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation.
No fasting is required before blood draw, and there is no time limit.
Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital.
The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
allele frequency of CMT genes
Zeitfenster: 1 month
|
Observed values of allele frequency of CMT genes
|
1 month
|
|
genotype frequency of CMT genes
Zeitfenster: 1 month
|
Observed values genotype frequency of CMT genes
|
1 month
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Xiaoxuan Liu, Peking University Third Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Neurologische Manifestationen
- Angeborene Anomalien
- Genetische Krankheiten, angeboren
- Neuromuskuläre Erkrankungen
- Neurodegenerative Krankheiten
- Erkrankungen des peripheren Nervensystems
- Neuromuskuläre Manifestationen
- Pathologische Zustände, Anatomisch
- Heredodegenerative Erkrankungen, Nervensystem
- Atrophie
- Missbildungen des Nervensystems
- Polyneuropathien
- Muskelatrophie
- Nervenkompressionssyndrome
- Charcot-Marie-Tooth-Krankheit
- Hereditäre sensorische und motorische Neuropathie
Andere Studien-ID-Nummern
- M2018206
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .